O meduloblastoma (MB) é um câncer do sistema nervoso central, de origem embrionária, que surge no cerebelo. É o tumor maligno cerebral mais frequente na infância e corresponde a aproximadamente 20% de todos os tumores intracranianos pediátricos. Atualmente, o tratamento é realizado com cirurgia, quimioterapia e radioterapia e está relacionado com diversos efeitos colaterais em médio e longo prazo. Diversos fatores contribuem para o seu desenvolvimento e progressão, entre estes, alterações nas vias de sinalização, como a Sonic Hedgehog (SHH) e Wingless. As modificações nos padrões epigenéticos, como a metilação do DNA, tem também um papel central na biologia deste tumor. Tais alterações comprometem funções básicas da célula como o controle da proliferação, sobrevivência celular e apoptose. Drogas epigenéticas como os inibidores de DNA metiltransferases (DNMTs) têm demonstrado efeitos antineoplásicos e resultados promissores para terapia do câncer. A Zebularina é um inibidor de DNMTs, que consequentemente reduz a metilação do DNA, e tem se mostrado uma importante droga antitumoral, com baixa toxicidade e atividade adjuvante à quimioterapia em tumores quimio-resistentes. Diversos estudos têm descrito seus efeitos em diferentes tipos de neoplasias, entretanto, não há relatos da sua ação em MB. Sendo assim, o presente trabalho teve como objetivo analisar os potenciais efeitos antineoplásicos da Zebularina em quatro linhagens de MB pediátrico (DAOY, ONS-76, UW402 e UW473). Foi observado que o tratamento com a Zebularina promoveu inibição da proliferação celular e da capacidade clonogênica, aumentou o número de células apoptóticas e células na fase S do ciclo celular (p<0,05). Adicionalmente, o tratamento induziu um aumento na expressão proteica de p53, p21 e Bax e uma diminuição da ciclina A, Bcl-2 e Survivina. Além disso, quando combinada com o quimioterápico vincristina agiu de modo sinérgico; e de modo antagônico quando combinada com a cisplatina. Através de análises de expressão gênica em larga escala (plataforma Agilent de microarray), foi encontrada diferentes vias moduladas pela droga, incluindo a dos Receptores Toll-Like e o aumento dos genes SUFU e BATF2. Aqui, foi encontrado que a Zebularina pode modular a ativação da via SHH, reduzindo os níveis de SMO, de GLI1 e de um de seus alvos, o PTCH1; contudo sem alterar os níveis de SUFU. Confirmou-se que o gene BATF2 é induzido pela Zebularina e possui regiões ricamente metiladas. Além disso, a baixa expressão do gene BATF2 está associada à um pior prognóstico em MB. Todos esses dados sugerem que a Zebularina pode ser uma droga em potencial para o tratamento adjuvante do MB / Medulloblastoma (MB) is an embryonal cerebellum tumor. It is the most common brain malignancy in children and accounts for approximately 20% of all pediatric intracranial tumors. Currently, treatment consists of surgery, chemotherapy and radiation and is associated to medium- and long-term side effects. Several factors contribute to the development and progression of MB, for instance, alterations in signaling pathways, such as Sonic Hedgehog (SHH) and Wingless. Epigenetic changes in DNA methylation patterns also play a central role in the biology of this tumor. Such changes are able to alter basic cell functions, controlling cell proliferation, survival and apoptosis. Epigenetic drugs as DNA methyltransferases (DNMTs) inhibitors have shown anticancer effects and promising results for cancer therapy. Zebularine is a low toxicity DNMTs inhibitor that induces DNA demethylation and has been reported as an important antitumor drug with adjuvant activity to chemotherapy in chemoresistant tumors. Studies have described its effects on different types of cancer, however, there are not data concerning its action in MB. Therefore, this study aimed to analyze the potential anticancer effects of Zebularine in four pediatric MB lines (UW402, UW473, ONS- 76 and DAOY). It was observed that treatment with Zebularine promoted inhibition of cell proliferation and clonogenic capacity, increased the number of apoptosis rate and cells in S phase of the cycle (p <0.05). In addition, the treatment induced an increasing in the protein expression of p53, p21 and Bax and a decreasing in cyclin A, Survivin and Bcl-2. Also, when combined with the chemotherapeutic agent vincristine acted synergistically but resulted in antagonism when combined with cisplatin. Through large-scale gene expression analysis (Agilent microarray platform), it was found different pathways modulated by Zebularine, including the Toll-Like Receptors pathway and the overexpression of SUFU and BATF2 genes. Zebularine was able to modulate SHH pathway activation, by reducing levels of SMO, GLI1 and one of its targets, PTCH1, whereas there were no changes in SUFU levels. It was confirmed that the gene BATF2 is induced by Zebularine and contains regions richly methylated. In addition, BATF2 low expression is associated with a worse prognosis in MB. All these data suggest that Zebularine may be a potential drug for the adjuvant treatment of MB

Development of enzymatic labelling methods has been driven by the importance of studying molecular structures and interactions to comprehend cellular processes. Methyltransferases (MTases), which regulate genetic expression by transferring a methyl group from the cofactor S-adenosyl-L-methionine (SAM) to DNA, histones and various proteins, have been shown to accept SAM analogues with an alternative alkyl group on the sulfonium centre. These alkyl groups can be transferred to the substrate, and with a further reaction can be selectively functionalized. Thus, MTases together with SAM analogues have emerged as novel labelling tools. The project aims to use MTases to obtain an orthogonal system that can selectively use a SAM cofactor analogue to transfer functional chains to proteins with a specific motif. To achieve selectivity of the system, the SAM analogue cofactor was modified on the ribose ring; to obtain a new transferase activity of the system, the transferable methyl on the sulfonium centre was changed to a different substituent. SAM analogues were produced enzymatically with hMAT2A by using 3'-deoxy-ATP and methionine or ethionine. Mutants of SET8 and novel substrates were designed to have modifications at residues in the active site, within the vicinity of the ribose ring of SAM, and were assessed for selective activity with the new analogue cofactor. The results showed that the new cofactor 3'-deoxy-S-adenosyl-L-methionine (3'dSAM) was efficient in the mono-methylation of the substrate peptide RFRKVL, and that the mutant SET8 C270V exhibited over 13 fold MTase activity in presence of 3'dSAM and the RFRKVL substrate, in comparison with the activity with the WT sequence RHRKVL and the SAM cofactor. In addition, glutathione S-transferase (GST) was used as a model protein to express the motif RFRKVL, to transform it into a potential substrate for SET8. Assessment of the MTase activity of SET8, 3'dSAM and the novel GST substrate indicated mono-methylation of the substrate. Moreover, the motif showed no interference with GST native activity. Based on the observations, a new enzymatic system shows higher selectivity with a new analogue cofactor over SAM to effectively methylate proteins expressing the consensus RFRKVL. Work on substrates, enzymes and cofactors should continue to obtain a functional-chain transferase activity of the enzymatic system.

All mC5-MTases are monomeric enzymes, except M. EcoHK31I and M. AquI which are MTases composed of two poly peptides. M.EcoHK31I is a mC5-MTase which recognizes the sequence 5-YGGCCR-3' and consists of polypeptide alpha and beta, with the latter gene encoded in an alternative reading frame of the former. All of the conserved motifs in mC5-MTases can be found in polypeptide alpha, except motif IX, which is located in polypeptide beta. Both polypeptides are required for in vitro methylation. / Methylation of cytosine residues in DNA occurs in diverse organisms from bacteria to humans. In higher eukaryotic organisms cytosine-C5 methyltransferase (mC5-MTase) is the only type of DNA MTase and it plays an important role in controlling a number of cellular processes including transcription genomic imprinting and DNA repair. In bacteria, there are three types of MTases, mC4-, mC5- and mAb-, classified according to the methylation site of the DNA. MTase and its cognate restriction endonuclease (ENase) form restriction-modification system. The role of MTase is to protect the host from its own ENase digestion while the ENase acts to degrade the invasion of foreign DNA. Sequence comparison of nearly 50 bacterial mC5-MTases has shown that these enzymes share an overall common protein architecture. Ten conserved motifs (I to X), each 10 to 20 amino acids in length, have been identified, five of which are highly conserved (I, IV, VI, VIII and X). In addition, all of these enzymes have a hypervariable region lying between motifs VIII and IX. It is called the target recognition domain (TRD), and is responsible for the specificity of DNA recognition and the choice of base to be methylated. / Since both of the polypeptides alpha and beta of M.EcoHK31I are sequenced and cloned into the expression vector separately, the role of DNA recognition and subunits interaction of individual polypeptides can be studied. By electromobility shift assay, we found that polypeptides alpha and beta complex recognize specific double strand oligos substrate. Polypeptide alpha-DNA formed aggregates and polypeptide beta alone did not bind DNA. Therefore, polypeptide beta assists the proper binding of polypeptide alpha to DNA substrate. Complex of polypeptide alpha and a polypeptide beta variant with N-terminal deletion of 41 amino acids showed a 16-fold reduction in methylation activity. Further deletion resulted in an inactive MTase. By surface plasmon resonance assay, the dissociation equilibrium constant (KD) of polypeptides alpha and beta complex was found to be 56.2nM and the KD for polypeptide alpha and DeltaN46-polypeptide beta complex was increased by about 95 folds, contributing by a drastic decrease in dissociate rate constant (kd) and an increase in association rate constant (ka). This indicated that the N-terminal region of polypeptide beta takes part in subunit interaction. / To pinpoint which amino acid residues located at the variable region of polypeptide alpha are important for DNA binding and subunits interaction, "charge-to-alanine scanning mutagenesis" were performed on 16 charge residues between Asp213 and Glu271 in the small domain. It was found that the five charge residues upstream of motif X are not required for activity. For other residues except K225, E240 and D245, the protein is active when the same charge is maintained. / Fung Wai To. / "March 2006." / Adviser: P. C. Shaw. / Source: Dissertation Abstracts International, Volume: 67-11, Section: B, page: 6376. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (p. 180-201). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstracts in English and Chinese. / School code: 1307.

Abstract not available

No description available.

Thesis (Ph. D.)--Institute of Paper Chemistry, 1983. / Includes bibliographical references (p. 113-122).

Thesis (M.Sc. (Biochemistry)--Mahidol University, 1982.

Thesis (doctoral)--Lund University, 1994. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Lund University, 1994. / Added t.p. with thesis statement inserted.

Thesis (Ph.D.)--Ohio University, August, 2005. / Includes bibliographical references (leaves 105-110)